Contribute Try STAT+ Today

WASHINGTON — A tiny eye drug company is about to walk away from Congress with a great big win: an extra two years of charging Medicare higher prices for its cataract surgery drug.

Tucked into some of the final pages of the sprawling, 2,232-page spending package congressional leaders unveiled late Wednesday are five pages detailing a complicated policy that represents a major win for Omeros, the Washington state-based company behind the cataract surgery drug Omidria. In fact, the language is painstakingly worded to ensure the policy affects Omeros and its product and almost no other drug companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • adam, do you ever mention that omidria is safer than any other alternative ? doctors and surgical centers, teaching hospitals prefer omidria over the unsafe practice of mixing ? safer enviornment for the patient ? your a real clown with an obvious vendetta against omeros.

  • Hey Adam, I thought you said Omero’s would never get pass-through. It’s amazing, you’ve had a personal vendetta against the Doctor and Omero’s, you’ve been paid to write lies, and help hedge funds short this stock time & time again. You are the type of person that makes the stock market an uneven playing field for the average retail investor (or anybody for that matter). No wonder you have been fired from so many places of employment, been investigated, and been in litigation because of your antics. It’s just a matter of time Mr. Adam!!

Comments are closed.